Alto Competitors
| ANRO Stock | 15.48 0.16 1.04% |
Alto Neuroscience vs DBV Technologies Correlation
Poor diversification
The correlation between Alto Neuroscience and DBVT is 0.73 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Alto Neuroscience and DBVT in the same portfolio, assuming nothing else is changed.
Moving together with Alto Stock
| 0.7 | MRK | Merck Company Earnings Call This Week | PairCorr |
Moving against Alto Stock
| 0.57 | T | ATT Inc Earnings Call This Week | PairCorr |
| 0.5 | MSFT | Microsoft | PairCorr |
| 0.44 | MMM | 3M Company | PairCorr |
| 0.35 | PG | Procter Gamble | PairCorr |
Alto Neuroscience Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Alto Neuroscience and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Alto and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Alto Neuroscience does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Alto Stock performing well and Alto Neuroscience Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Alto Neuroscience's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CLLS | 3.74 | 0.29 | 0.06 | 0.58 | 4.25 | 9.24 | 29.31 | |||
| ACIU | 3.76 | 0.06 | 0.03 | 0.08 | 4.81 | 9.09 | 26.05 | |||
| AMRN | 2.38 | (0.34) | 0.00 | (0.66) | 0.00 | 4.89 | 21.26 | |||
| LRMR | 3.43 | (0.15) | 0.00 | 1.18 | 0.00 | 6.96 | 20.14 | |||
| CTNM | 3.33 | 0.57 | 0.11 | (0.67) | 4.02 | 7.99 | 23.16 | |||
| ALDX | 3.61 | 0.18 | 0.03 | (1.73) | 4.37 | 6.27 | 42.93 | |||
| DRTS | 3.89 | 0.76 | 0.21 | 0.26 | 3.55 | 10.48 | 28.89 | |||
| SLN | 2.87 | (0.55) | 0.00 | (0.87) | 0.00 | 6.88 | 22.91 | |||
| KRRO | 5.28 | (0.57) | 0.00 | (0.05) | 0.00 | 12.24 | 91.55 | |||
| DBVT | 4.23 | 0.83 | 0.17 | (0.80) | 3.79 | 10.53 | 36.36 |
Cross Equities Net Income Analysis
Compare Alto Neuroscience and related stocks such as Cellectis SA, AC Immune, and Amarin PLC Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLLS | (4.4 M) | (30.9 M) | (29.5 M) | (84.3 M) | 24.3 K | (22.5 M) | (63.9 M) | (99.4 M) | (78.7 M) | (90.7 M) | (72.6 M) | (86.3 M) | (98.7 M) | (101.1 M) | (36.8 M) | (33.1 M) | (34.7 M) |
| ACIU | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | 10.7 M | 20.3 M | (7.1 M) | (26.4 M) | (51 M) | 45.4 M | (61.9 M) | (73 M) | (70.8 M) | (54.2 M) | (50.9 M) | (45.8 M) | (43.5 M) |
| AMRN | 900 K | (69.4 M) | (179.2 M) | (166.2 M) | (56.4 M) | (115.2 M) | (86.3 M) | (67.9 M) | (116.4 M) | (22.6 M) | (18 M) | 7.7 M | (105.8 M) | (59.1 M) | (82.2 M) | (74 M) | (77.7 M) |
| LRMR | (13.2 M) | (13.2 M) | (13.9 M) | (14 M) | (36.6 M) | (74.3 M) | (57.9 M) | (52 M) | (61.4 M) | (23.1 M) | (42.3 M) | (50.3 M) | (34.2 M) | (36.9 M) | (80.6 M) | (72.5 M) | (68.9 M) |
| CTNM | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (24.3 M) | 22.7 M | (42.3 M) | (48.6 M) | (46.2 M) |
| ALDX | (2.4 M) | (2.4 M) | (23.1 M) | 13.1 M | (5.2 M) | (12.1 M) | (18.7 M) | (22.3 M) | (38.9 M) | (60.8 M) | (37.6 M) | (57.8 M) | (62 M) | (37.5 M) | (55.9 M) | (50.3 M) | (47.8 M) |
| DRTS | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.5 M) | (8.9 M) | (27.3 M) | (33.8 M) | (29.2 M) | (31.8 M) | (28.6 M) | (30 M) |
| SLN | (874 K) | (5.7 M) | (26.3 M) | (9 M) | (11.1 M) | (6.6 M) | (8.4 M) | (1.6 M) | (18.4 M) | (19.6 M) | (32.5 M) | (39.4 M) | (50.3 M) | (43.3 M) | (45.3 M) | (40.8 M) | (38.7 M) |
| KRRO | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (19.2 M) | (18.7 M) | (26.5 M) | (84.7 M) | (58 M) | (81.2 M) | (83.6 M) | (75.2 M) | (79 M) |
| DBVT | (6.1 M) | (9.4 M) | (17 M) | (26.6 M) | (29.1 M) | (48.5 M) | (126.3 M) | (177.2 M) | (190.3 M) | (172 M) | (159.6 M) | (97.8 M) | (96.3 M) | (72.7 M) | (113.7 M) | (102.3 M) | (107.5 M) |
Alto Neuroscience and related stocks such as Cellectis SA, AC Immune, and Amarin PLC Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Alto Neuroscience financial statement analysis. It represents the amount of money remaining after all of Alto Neuroscience operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Alto Neuroscience Competitive Analysis
The better you understand Alto Neuroscience competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Alto Neuroscience's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Alto Neuroscience's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Alto Neuroscience Competition Performance Charts
Five steps to successful analysis of Alto Neuroscience Competition
Alto Neuroscience's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Alto Neuroscience in relation to its competition. Alto Neuroscience's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Alto Neuroscience in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Alto Neuroscience's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Alto Neuroscience, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Alto Neuroscience position
In addition to having Alto Neuroscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run High Dividend Yield ETFs Thematic Idea Now
High Dividend Yield ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Dividend Yield ETFs theme has 111 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Dividend Yield ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Alto Neuroscience Correlation with its peers. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Will Pharmaceuticals sector continue expanding? Could Alto diversify its offerings? Factors like these will boost the valuation of Alto Neuroscience. If investors know Alto will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alto Neuroscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Alto Neuroscience requires distinguishing between market price and book value, where the latter reflects Alto's accounting equity. The concept of intrinsic value—what Alto Neuroscience's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Alto Neuroscience's price substantially above or below its fundamental value.
Understanding that Alto Neuroscience's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alto Neuroscience represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Alto Neuroscience's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.